24X National Exchange Sets Aggressive New Pricing to Attract Liquidity Providers
Pricing program launched today following its recent filing with the SECSTAMFORD, Conn., March 2,…
This World Hearing Day, Cochlear brings the world’s first and only smart hearing implant system to India
The new Cochlear™ Nucleus® Nexa® System is the first and only hearing…
Hisense Leads Global TV Shipments in 2025 Across 100-Inch+ and Laser TVs
QINGDAO, China, March 2, 2026 /PRNewswire/ -- Hisense, a leading brand in global…
UfiSpace Unveils AIOptimized 1.6T Open Networking Portfolio at MWC Barcelona 2026
BARCELONA, Spain, March 2, 2026 /PRNewswire/ -- UfiSpace, a leader in open networking…
Setting the benchmark in sustainable comminution: Metso and Loesche introduce transformative dry grinding technology
ESPOO, Finland, March 2, 2026 /PRNewswire/ -- Metso Corporation and Loesche GmbH…
Central Phuket Unveils US$836 Million Expansion to Drive Phuket’s Transformation into a Global Luxury Living and Investment Hub
PHUKET, Thailand, March 2, 2026 /PRNewswire/ -- Central Pattana Plc., the retail-led…
The Wynn Signature Chinese Wine Awards Judging Week Returns for a Third Consecutive Year in March
23 of the world's leading wine experts meet in Macao to judge…
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142)…
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
March 01, 2026 09:45 ET | Source: Celldex Therapeutics, Inc. - Late…
